← Back to all protocols
23

Acute Hypomagnesaemia — AdultElectrolyte Emergencies

1 · Quick ED Algorithm

Low Mg²⁺ → assess symptoms + ECG → check K⁺ / Ca²⁺ / renal function
↓
Mild + asymptomatic → oral Mg²⁺ + treat the cause
↓
Severe / symptomatic → IV Mg²⁺ + monitor
↓
Torsades / life-threatening arrhythmia → resuscitation + IV Mg²⁺ + correct K⁺ + remove causes
↓
Recheck Mg²⁺ / K⁺ / Ca²⁺ → treat the underlying cause

2 · Initial Assessment

  • ABCDE approach
  • Assess haemodynamic stability
  • 12-lead ECG
  • Cardiac monitoring when clinically indicated
  • IV access for significant/symptomatic hypomagnesaemia
  • Repeat magnesium if a laboratory error is suspected
  • Check: magnesium, potassium, calcium, sodium, phosphate, renal function/eGFR, glucose, ECG, and acid–base status where clinically relevant
  • Hypomagnesaemia commonly coexists with hypokalaemia and hypocalcaemia.
  • Related EMOnCall protocols: Acute Hyperkalaemia — Adult · Acute Hypokalaemia — Adult

3 · Severity Classification

  • Mild / asymptomatic: serum magnesium approximately 0.5–0.7 mmol/L (some sources use 0.4–0.7 mmol/L)
  • Severe / symptomatic: serum magnesium approximately <0.5 mmol/L (some sources use <0.4 mmol/L)
  • Normal reference range: approximately 0.7–1.0 mmol/L (check your local laboratory range)
  • Treat these as approximate bands, not hard cut-offs — sources vary slightly in exactly where they draw the mild/severe boundary
  • Distinguish a laboratory abnormality from clinically significant hypomagnesaemia — base treatment decisions on the whole picture: absolute magnesium level, symptoms, ECG abnormalities, arrhythmia, seizures, associated electrolyte abnormalities, renal function, and the rate of decline

4 · Clinical Features

  • Neuromuscular: weakness, tremor, muscle cramps, fasciculations, tetany, hyperreflexia, seizures, altered mental status
  • Cardiac: palpitations, prolonged QT, ventricular ectopy, atrial/ventricular arrhythmias, torsades de pointes
  • Associated electrolyte abnormalities: hypokalaemia, hypocalcaemia, and hypokalaemia that is refractory to potassium replacement alone
  • Consider hypomagnesaemia in unexplained or refractory hypokalaemia.

5 · ECG

  • QT prolongation
  • Ventricular ectopy
  • Torsades de pointes
  • Other potentially serious arrhythmias
  • A normal ECG does NOT exclude clinically significant hypomagnesaemia.

6 · When to Replace Magnesium — Oral vs IV

  • Oral replacement is appropriate for mild, asymptomatic hypomagnesaemia in a patient who can safely take oral medication
  • IV replacement is indicated for: severe hypomagnesaemia; symptomatic patients; seizures; significant arrhythmia; torsades de pointes; inability to tolerate oral treatment; significant ongoing losses; or associated severe electrolyte abnormalities where IV replacement is clinically appropriate
  • The exact threshold for choosing IV over oral is a clinical judgement based on severity, symptoms and context — not a single fixed number

7 · Oral Magnesium

  • Commonly used preparations: magnesium aspartate sachets (~10 mmol elemental magnesium per sachet); magnesium citrate tablets (~4 mmol); magnesium glycerophosphate preparations (~1.6–5 mmol per dose)
  • Dose — refers to mmol of elemental magnesium, not the salt weight: a typical adult starting dose is 10 mmol once or twice daily (e.g. one magnesium aspartate sachet dissolved in 50–200 mL water, tea or juice), adjusted to response and local formulary
  • Duration/monitoring: an initial course of around 3 days, then review the need for continued replacement based on repeat magnesium levels
  • Adverse effects: diarrhoea is common and dose-limiting; GI tolerability often limits how much can be replaced orally
  • Limitation: oral absorption is limited and slow — not suitable for severe or symptomatic hypomagnesaemia, or when rapid correction is needed

8 · IV Magnesium Replacement

  • Severe but stable hypomagnesaemia (including oral-intolerant patients with milder deficiency): magnesium sulfate 8 mmol (4 mL of 50% solution) diluted in 100 mL 0.9% sodium chloride or 5% glucose, IV over 1 hour
  • Severe / symptomatic hypomagnesaemia (excluding torsades/life-threatening arrhythmia — see section 9): magnesium sulfate 20 mmol (10 mL of 50% solution) diluted in at least 100 mL 0.9% sodium chloride or 5% glucose, IV over at least 3 hours, not exceeding 8 mmol/hour; further doses may be given based on repeat levels, up to a cumulative course of around 160 mmol over 5 days in ongoing severe deficiency
  • Maximum peripheral concentration: approximately 5% magnesium sulfate solution (i.e. 20 mmol/100 mL) — the 50% concentrate must always be diluted before use
  • Cardiac monitoring: recommended during IV magnesium in patients with significant symptoms (tetany, seizures, arrhythmia); monitor BP, heart rate and respiratory rate during any IV magnesium infusion
  • Torsades de pointes / life-threatening ventricular arrhythmia is treated differently and faster — see the dedicated emergency section below, not the routine doses above

9 · Torsades de Pointes / Life-Threatening Ventricular Arrhythmia

  • Immediate ABC assessment and continuous cardiac monitoring
  • Defibrillation according to current ALS guidance if the rhythm is pulseless or haemodynamically unstable — do not delay defibrillation to give magnesium if the patient is peri-arrest/unstable
  • IV magnesium (peri-arrest, pulse present): magnesium sulfate 2 g (8 mmol) IV over 10 minutes; may be repeated once after 5–15 minutes if the arrhythmia persists
  • IV magnesium (pulseless cardiac arrest due to torsades): give as a rapid IV bolus (over 1–2 minutes) in line with standard ALS drug administration, then continue standard ALS
  • Correct hypokalaemia simultaneously — hypokalaemia and hypomagnesaemia frequently coexist and both promote torsades
  • Stop/review QT-prolonging medications immediately
  • Treat reversible causes (electrolyte abnormalities, bradycardia, drug toxicity)
  • Senior/critical care involvement early — this is a medical emergency
  • This regimen is a specific exception to routine magnesium dosing above; it is faster and more concentrated because of the immediate arrhythmia risk

10 · Seizures / Neurological Symptoms

  • Manage active seizures according to standard ALS/emergency seizure management principles
  • Give IV magnesium replacement where hypomagnesaemia is thought to be contributing (see section 8)
  • Correct associated electrolyte abnormalities (potassium, calcium) alongside magnesium
  • Investigate and treat the underlying cause of the seizure — do not assume every seizure is caused by hypomagnesaemia; continue standard seizure work-up

11 · Associated Hypokalaemia

  • Magnesium deficiency can cause renal potassium wasting
  • Hypokalaemia may be refractory to potassium replacement until magnesium is corrected
  • Check magnesium in any significant or unexplained hypokalaemia, and replace it when deficient
  • Continue potassium monitoring and replacement according to the clinical situation alongside magnesium correction
  • See the full EMOnCall Hypokalaemia protocol: Acute Hypokalaemia — Adult

12 · Associated Hypocalcaemia

  • Hypomagnesaemia can contribute to hypocalcaemia, partly through impaired parathyroid hormone secretion and action
  • Assess serum calcium in significant hypomagnesaemia
  • Consider ionised calcium where clinically appropriate, particularly if albumin-corrected total calcium is difficult to interpret
  • Correct significant calcium abnormalities according to the clinical context — magnesium correction alone may not fully resolve hypocalcaemia if calcium replacement is also needed

13 · Find and Treat the Cause

  • Gastrointestinal: diarrhoea; vomiting; malabsorption; chronic proton-pump-inhibitor-associated deficiency; high-output GI losses (fistulae, stomas)
  • Renal: diuretics; renal magnesium wasting; aminoglycosides; cisplatin; calcineurin inhibitors; other nephrotoxic medications
  • Other: alcohol-related nutritional deficiency; malnutrition; refeeding syndrome; pancreatitis; uncontrolled diabetes/osmotic diuresis; critical illness
  • Medication review: identify and reassess any medications contributing to magnesium loss

14 · Drug-Induced Hypomagnesaemia

  • Proton-pump inhibitors
  • Loop diuretics
  • Thiazide diuretics
  • Aminoglycosides
  • Cisplatin
  • Calcineurin inhibitors (e.g. tacrolimus, ciclosporin)
  • Other recognised magnesium-wasting medications
  • Review and modify contributing medications where clinically appropriate — weigh the indication for the drug against the severity of hypomagnesaemia

15 · Renal Impairment

  • RENAL IMPAIRMENT → HIGHER RISK OF MAGNESIUM ACCUMULATION.
  • Check renal function before IV replacement
  • Severe renal impairment (eGFR <30 mL/min): reduce IV magnesium doses to approximately 50% or less of the standard dose
  • Give single, smaller doses and reassess using repeat serum magnesium levels rather than committing to a full multi-day course upfront
  • Monitor magnesium more closely for accumulation/toxicity
  • Seek senior/renal advice for severe renal impairment or dialysis-dependent patients

16 · Monitoring

  • Serum magnesium: recheck at least 12 hours after an IV infusion, ideally sampled from the arm opposite the infusion site
  • Potassium and calcium: monitor daily alongside magnesium (U&E including Mg, K, Ca) during replacement
  • Renal function: monitor throughout, particularly with repeated or higher-dose IV replacement
  • ECG / cardiac rhythm: continuous monitoring during IV replacement in symptomatic patients or where arrhythmia/ECG changes are present
  • Neurological symptoms: reassess tetany, tremor, hyperreflexia and mental status as treatment progresses
  • Infusion-site monitoring throughout peripheral IV replacement
  • Frequency should be individualised to severity, route, dose, infusion rate, renal function and symptoms/arrhythmia — increase monitoring frequency for any of these that are more severe

17 · Disposition

  • Possible ED discharge: mild/asymptomatic; cause identified and addressed; safe oral replacement in place; no significant ECG abnormality; appropriate follow-up arranged
  • Admission: severe hypomagnesaemia; symptomatic patients; seizures; significant arrhythmia; significant associated electrolyte abnormalities; ongoing losses; inability to tolerate oral replacement; significant renal or medical comorbidity
  • ICU/HDU / urgent senior review: torsades; unstable arrhythmia; seizures; haemodynamic instability; severe electrolyte abnormalities; need for intensive IV replacement/monitoring

18 · Red Flags — Urgent Senior / Critical Care Review

  • Torsades de pointes
  • Ventricular arrhythmia
  • Significant QT prolongation
  • Seizures
  • Severe symptomatic hypomagnesaemia
  • Severe hypokalaemia associated with magnesium deficiency
  • Severe hypocalcaemia
  • Significant renal impairment
  • Recurrent/refractory hypomagnesaemia

19 · Safety Warnings

  • CHECK RENAL FUNCTION BEFORE IV MAGNESIUM.
  • DO NOT GIVE IV MAGNESIUM AS A RAPID IV PUSH UNLESS SPECIFICALLY INDICATED BY THE EMERGENCY/RESUSCITATION PROTOCOL (i.e. torsades/pulseless arrest — section 9)
  • USE THE CORRECT PREPARATION AND CONCENTRATION.
  • MONITOR FOR MAGNESIUM TOXICITY IN RENAL IMPAIRMENT.
  • CHECK AND CORRECT ASSOCIATED HYPOKALAEMIA.
  • CHECK CALCIUM.
← Back to all protocols